Respiratory System
Overview
This report looks at prescribing trends in primary care for the Respiratory System at SICBl and ICB level with particular focus on bronchodilators and corticosteroids. Prescribing data is weighted with QoF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for respiratory drugs based on the NHS England Right Care indicators.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
April 2020 to March 2023
Drugs for Dementia
Overview
This report looks at prescribing trends in primary care for Drugs for Dementia at SICBl and ICB level with particular focus on low strength antipsychotics. Prescribing data is weighted with QoF registers.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
April 2020 to March 2023
Cardiovascular System
Overview
This report looks at prescribing trends in primary care for the Cardiovascular System at SICBl and ICB level with particular focus on anticoagulants, antiplatelets and lipid-regulating. Prescribing data is weighted with QoF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for cardiovascular drugs based on the NHS England Right Care indicators.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
April 2020 to March 2023
Drugs used in Diabetes
Overview
This report looks at prescribing trends in primary care for Drugs used in Diabetes at SICBl and ICB level with particular focus on insulins, anti-diabetic drugs and diagnostic & monitoring devices. Prescribing data is weighted with QoF registers, and also uses HES data to measure prescribing to outcomes.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
April 2020 to March 2023
Monthly Formulary Amendments – March 2023
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, RMOC Guidance, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in March 2023.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Transfer of prescribing from private provider to NHS GP
Overview
Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.
This publication aims to provide guidance on what NHS prescribers need to be aware of when they are asked by a private healthcare provider, and/or patient, to take on the regular prescribing of a medication for a patient, including medicines supplied under formal shared care agreements. Based on suggested best practice it discusses the principles which underpin the transfer of patients from private to NHS provision and highlights Shared Care specific, and ethical considerations.
Monthly Horizon Scanning Report – March 2023
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.
Considerations for Sustainable Inhaler Prescribing
Overview
Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.
Inhalers account for approximately 3% of all NHS carbon emissions. Reducing the carbon impact from inhaler prescribing has been identified as a significant area of focus for delivering a net zero NHS. This document aims to outline strategies that can be considered to promote optimal respiratory care, while minimising the environmental impact from inhalers and consequences of suboptimal disease management
NICE TA875; Semaglutide for managing obesity: A briefing for ICSs
In March 2023 NICE published TA875: Technology Appraisal guidance for semaglutide (Wegovy®) for managing overweight and obesity. The guidance recommends semaglutide as an option for weight management when prescribed by a specialist service alongside a reduced-calorie diet and increased physical activity in adults if they meet the criteria specified. This briefing aims to provide advice to prescribers on how the treatment can be accessed and which patient groups are eligible to receive Wegovy®. The document explains some of the limitations of the treatment and the evidence base, as described by NICE and may help to manage patient expectations.
At the time of publication the product is not yet available in the UK.
Formulary assessment – Tacalcitol (Curatoderm) Lotion and Ointment
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.